// App-Quantinova.ai

297 : Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.

Researchers

Presenter

  • Jean-Luc Van Laethem

Principal Investigators

  • Mark Karwal

  • Chris Verslype

  • Hans Van Vlierberghe

  • Adel Kardosh

  • Vittorina Zagonel

  • Per Stal

  • Debashis Sarker

  • Daniel H. Palmer

  • Arndt Vogel

  • Julien Edeline

  • Stphane Cattan

  • Masatoshi Kudo

  • Ann-Lii Cheng

  • Sadahisa Ogasawara

  • Abby B. Siegel

  • Michael Jon Chisamore

  • Anran Wang

  • Andrew X. Zhu

Medical Centers

  • Erasme Hospital, Bruxelles, Belgium

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • University of Iowa, Iowa City, IA

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Ghent University Hospital, Ghent, Belgium

  • Oregon Health and Science University, Portland, OR

  • Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy

  • Karolinska Institutet, Stockholm, Sweden

  • King's College Hospital, Institute of Liver Studies, London, United Kingdom

  • University of Liverpool, Liverpool, United Kingdom

  • Medizinische Hochschule Hannover, Hannover, Germany

  • Centre Eugene-Marquis, Rennes, France

  • Hopital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lillie, France

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan

  • Merck & Co., Inc., Kenilworth, NJ

  • Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • Belgium

  • United States

  • Italy

  • Sweden

  • United Kingdom

  • Germany

  • France

  • Japan

  • Taiwan

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved